184 related articles for article (PubMed ID: 1631151)
1. An infrequent point mutation of the p53 gene in human nasopharyngeal carcinoma.
Sun Y; Hegamyer G; Cheng YJ; Hildesheim A; Chen JY; Chen IH; Cao Y; Yao KT; Colburn NH
Proc Natl Acad Sci U S A; 1992 Jul; 89(14):6516-20. PubMed ID: 1631151
[TBL] [Abstract][Full Text] [Related]
2. [A hot-spot mutation of p53 gene in nasopharyngeal carcinoma].
Chen R; Zhu D; Yin W
Zhonghua Zhong Liu Za Zhi; 1995 Nov; 17(6):401-4. PubMed ID: 8697986
[TBL] [Abstract][Full Text] [Related]
3. Absence of p53 gene mutations in primary nasopharyngeal carcinomas.
Spruck CH; Tsai YC; Huang DP; Yang AS; Rideout WM; Gonzalez-Zulueta M; Choi P; Lo KW; Yu MC; Jones PA
Cancer Res; 1992 Sep; 52(17):4787-90. PubMed ID: 1511442
[TBL] [Abstract][Full Text] [Related]
4. p53 mutation in human nasopharyngeal carcinomas.
Lo KW; Mok CH; Huang DP; Liu YX; Choi PH; Lee JC; Tsao SW
Anticancer Res; 1992; 12(6B):1957-63. PubMed ID: 1295443
[TBL] [Abstract][Full Text] [Related]
5. Mutations clustered in exon 5 of the p53 gene in primary nasopharyngeal carcinomas from southeastern Asia.
Chakrani F; Armand JP; Lenoir G; Ju LY; Liang JP; May E; May P
Int J Cancer; 1995 May; 61(3):316-20. PubMed ID: 7729941
[TBL] [Abstract][Full Text] [Related]
6. Nasopharyngeal carcinoma shows no detectable retinoblastoma susceptibility gene alterations.
Sun Y; Hegamyer G; Colburn NH
Oncogene; 1993 Mar; 8(3):791-5. PubMed ID: 8437863
[TBL] [Abstract][Full Text] [Related]
7. No point mutation but decreased expression of the p16/MTS1 tumor suppressor gene in nasopharyngeal carcinomas.
Sun Y; Hildesheim A; Lanier AE; Cao Y; Yao KT; Raab-Traub N; Yang CS
Oncogene; 1995 Feb; 10(4):785-8. PubMed ID: 7862458
[TBL] [Abstract][Full Text] [Related]
8. No point mutation but a codon 31ser-->arg polymorphism of the WAF-1/CIP-1/p21 tumor suppressor gene in nasopharyngeal carcinoma (NPC): the polymorphism distinguishes Caucasians from Chinese.
Sun Y; Hildesheim A; Li H; Li Y; Chen JY; Cheng YJ; Hayes RB; Rothman N; Bi WF; Cao Y
Cancer Epidemiol Biomarkers Prev; 1995; 4(3):261-7. PubMed ID: 7606201
[TBL] [Abstract][Full Text] [Related]
9. p53 inactivating mutations in Chinese nasopharyngeal carcinomas.
Lung ML; Hu Y; Cheng Y; Li MF; Tang CM; O SK; Iggo RD
Cancer Lett; 1998 Nov; 133(1):89-94. PubMed ID: 9929165
[TBL] [Abstract][Full Text] [Related]
10. [Mutation and expression of p53 gene in nasopharyngeal carcinoma, cervical carcinoma and lung cancer].
Xie Y; Yao K; Hu W
Zhonghua Bing Li Xue Za Zhi; 1997 Aug; 26(4):229-32. PubMed ID: 10072870
[TBL] [Abstract][Full Text] [Related]
11. [The expression of tumor suppressor gene p53 and Rb gene in nasopharyngeal carcinoma].
Song Y; Wang L; Huang G; Huang R; Yuan S; Liu Y
Hua Xi Yi Ke Da Xue Xue Bao; 1997 Sep; 28(3):268-71. PubMed ID: 10684031
[TBL] [Abstract][Full Text] [Related]
12. A molecular study of EBV DNA and p53 mutations in nasopharyngeal carcinoma of Saudi Arab patients.
Nasrin N; Taiba K; Hannan N; Hannan M; al-Sedairy S
Cancer Lett; 1994 Jul; 82(2):189-98. PubMed ID: 7914150
[TBL] [Abstract][Full Text] [Related]
13. [Screening for mutations in the hotspot mutation regions of PIK3CA gene in nasopharyngeal carcinoma].
Liu P; Li DJ; Qin HD; Zhang RH; Chen LZ; Zeng YX
Ai Zheng; 2007 Jan; 26(1):15-20. PubMed ID: 17222361
[TBL] [Abstract][Full Text] [Related]
14. Alterations of BLU, a candidate tumor suppressor gene on chromosome 3p21.3, in human nasopharyngeal carcinoma.
Liu XQ; Chen HK; Zhang XS; Pan ZG; Li A; Feng QS; Long QX; Wang XZ; Zeng YX
Int J Cancer; 2003 Aug; 106(1):60-5. PubMed ID: 12794757
[TBL] [Abstract][Full Text] [Related]
15. Mutational analysis of p53 and RB2/p130 genes in Malaysian nasopharyngeal carcinoma samples: a preliminary report.
Hoe SL; Sam CK
Malays J Pathol; 2006 Jun; 28(1):35-9. PubMed ID: 17694957
[TBL] [Abstract][Full Text] [Related]
16. Presence of p53 mutations in primary nasopharyngeal carcinoma (NPC) in non-Asians of Los Angeles, California, a low-risk population for NPC.
Van Tornout JM; Spruck CH; Shibata A; Schmutte C; Gonzalez-Zulueta M; Nichols PW; Chandrasoma PT; Yu MC; Jones PA
Cancer Epidemiol Biomarkers Prev; 1997 Jul; 6(7):493-7. PubMed ID: 9232335
[TBL] [Abstract][Full Text] [Related]
17. Promoter hypermethylation along with LOH, but not mutation, contributes to inactivation of DLC-1 in nasopharyngeal carcinoma.
Feng X; Ren C; Zhou W; Liu W; Zeng L; Li G; Wang L; Li M; Zhu B; Yao K; Jiang X
Mol Carcinog; 2014 Nov; 53(11):858-70. PubMed ID: 23908159
[TBL] [Abstract][Full Text] [Related]
18. Dosage-dependent dominance over wild-type p53 of a mutant p53 isolated from nasopharyngeal carcinoma.
Sun Y; Dong Z; Nakamura K; Colburn NH
FASEB J; 1993 Jul; 7(10):944-50. PubMed ID: 8344492
[TBL] [Abstract][Full Text] [Related]
19. p53 tumor suppressor gene mutation in early esophageal precancerous lesions and carcinoma among high-risk populations in Henan, China.
Gao H; Wang LD; Zhou Q; Hong JY; Huang TY; Yang CS
Cancer Res; 1994 Aug; 54(16):4342-6. PubMed ID: 8044781
[TBL] [Abstract][Full Text] [Related]
20. A lack of association between p53 mutations and recurrent nasopharyngeal carcinomas refractory to radiotherapy.
Chang KP; Hao SP; Lin SY; Tsao KC; Kuo TT; Tsai MH; Tseng CK; Tsang NM
Laryngoscope; 2002 Nov; 112(11):2015-9. PubMed ID: 12439172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
